Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Cadisegliatin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    VTv Therapeutics at 38th Annual Roth Conference
    VTv Therapeutics at 38th Annual Roth Conference

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256202/0/en/vTv-Therapeutics-to-Participate-in-the-38th-Annual-ROTH-Conference.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    VTv Therapeutics Reveals 2025 Financials, Corporate Update
    VTv Therapeutics Reveals 2025 Financials, Corporate Update

    10 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/10/3253292/0/en/vTv-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    10 Mar 2026
    Share Share
    VTV Therapeutics Updates License Deal For PDE4 Inhibitor HPP737
    VTV Therapeutics Updates License Deal For PDE4 Inhibitor HPP737

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3230224/0/en/vTv-Therapeutics-Amends-License-Agreement-with-Newsoara-Biopharma-Co-Ltd-for-PDE4-inhibitor-HPP737.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share
    VTV Therapeutics, M42 Submit Cadisegliatin Phase 2 Protocol in US
    VTV Therapeutics, M42 Submit Cadisegliatin Phase 2 Protocol in US

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3208170/0/en/vTv-Therapeutics-and-M42-s-IROS-Announce-Submission-of-Phase-2-Clinical-Study-Protocol-for-Cadisegliatin-in-Type-2-Diabetes-to-the-United-Arab-Emirates-Department-of-Health.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    USPTO Allows vTv Therapeutics' Cadisegliatin Patent
    USPTO Allows vTv Therapeutics' Cadisegliatin Patent

    11 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/11/3130827/0/en/vTv-Therapeutics-Announces-USPTO-Allowance-of-Patent-Covering-Cadisegliatin.html

    GLOBENEWSWIRE
    11 Aug 2025
    Share Share
    vTv Therapeutics Reinitiates Screening in CATT1 Phase 3 Trial
    vTv Therapeutics Reinitiates Screening in CATT1 Phase 3 Trial

    15 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/15/3082480/0/en/vTv-Therapeutics-Announces-Reinitiation-of-Screening-in-CATT1-Phase-3-Trial-Evaluating-Potential-First-in-Class-Liver-Selective-Glucokinase-Activator-Cadisegliatin-for-Type-1-Diabe.html

    GLOBENEWSWIRE
    15 May 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.